BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers

(2013) E H Lips et al.   BRITISH JOURNAL OF CANCER

Hereditary breast cancer: beyond BRCA genetic analysis; PALB2 emerges

(2012) Nikoleta Poumpouridou et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression

(2012) Amanjit Bal et al.   VIRCHOWS ARCHIV

Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors

(2012) Janneke E. Jaspers et al.   Cancer Discovery

Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents

(2012) Nicolai J. Birkbak et al.   Cancer Discovery

Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer

(2011) F. Rojo et al.   ANNALS OF ONCOLOGY

PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy

(2011) Pawel Domagala et al.   BREAST CANCER RESEARCH AND TREATMENT

Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer

(2011) Heide Hellebrand et al.   HUMAN MUTATION

Cytoplasmic Poly(Adenosine Diphosphate–Ribose) Polymerase Expression Is Predictive and Prognostic in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy

(2011) Gunter von Minckwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

High Nuclear Poly(Adenosine Diphosphate-Ribose) Polymerase Expression Is Predictive forBRCA1- andBRCA2-Deficient Breast Cancer

(2011) Luka Ozretić et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

(2011) Karen A Gelmon et al.   LANCET ONCOLOGY

P53-Binding protein 1: A new player for tumorigenesis and a new target for breast cancer treatment

(2011) Qiang Huo et al.   MEDICAL HYPOTHESES

BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability

(2011) A. Aly et al.   Journal of Molecular Cell Biology

Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy

(2010) E. H. Lips et al.   ANNALS OF ONCOLOGY

53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks

(2010) Samuel F. Bunting et al.   CELL

BRCA1 CpG Island Hypermethylation Predicts Sensitivity to Poly(Adenosine Diphosphate)- Ribose Polymerase Inhibitors

(2010) Jurgen Veeck et al.   JOURNAL OF CLINICAL ONCOLOGY

Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2

(2010) Yvette Drew et al.   JNCI-Journal of the National Cancer Institute

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

(2010) Peter Bouwman et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination

(2010) Rémi Buisson et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

53BP1: function and mechanisms of focal recruitment

(2009) Jennifer E. FitzGerald et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines

(2009) S Mallett et al.   BRITISH JOURNAL OF CANCER

PARP Inhibitors: Will the New Class of Drugs Match the Hype?

(2009) Rabiya S. Tuma   JNCI-Journal of the National Cancer Institute

An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors

(2008) Xuesong Liu et al.   ANALYTICAL BIOCHEMISTRY